Literature DB >> 30183077

Clonal evolution in long-term follow-up patients with hepatocellular carcinoma.

Geng Chen1,2,3, Zhixiong Cai1,2,3, Zhenli Li1,2, Xiuqing Dong1,2, Haipo Xu1,2, Jianling Lin1,2, Lihong Chen1,2, Huqin Zhang3, Xiaolong Liu1,2, Jingfeng Liu1,2,4.   

Abstract

To investigate tumor clonal evolution in hepatocellular carcinoma (HCC), we collected 31 tumor samples,16 peritumor samples and matched PBMCs from 11 long-term follow-up patients with HCC. Whole-exome sequencing was performed to obtain SNVs and CNVs for each sample. An average of 652.2 somatic mutations were identified in each patient and the mean percentage of nonubiquitous tumor mutations was 63.7% (range, 0.7%-100%), reflecting the variety of tumor heterogeneity. Further analysis of clonal evolution was conducted based on mutation clustering results and revealed that different clonal evolution patterns indeed existed in single and multifocal HCC while these patterns were significantly correlated to patients' clinical course. These patterns clearly demonstrated different mechanisms of tumor recurrence. During tumor clonal evolution, potential therapeutic targets also emerged and vanished dynamically. Moreover, mutation analysis revealed that the contribution of mutational signature was correlated with clonal evolution history. Target sequencing of follow-up plasma samples also confirmed that ctDNA level could dynamically reflect tumor clonal/subclonal burden. By investigating clonal evolution in HCC patients, our analysis revealed that different patterns indeed existed during HCC progression and proposed a novel strategy for identifying the origin of recurrent tumor as well as optimizing treatment selection.
© 2018 UICC.

Entities:  

Keywords:  circulating tumor DNA; clonal evolution; hepatocellular carcinoma; mutational signature; tumor heterogeneity

Mesh:

Year:  2018        PMID: 30183077     DOI: 10.1002/ijc.31844

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity.

Authors:  Zhi-Yi Luo; Qi Tian; Niang-Mei Cheng; Wen-Han Liu; Ye Yang; Wei Chen; Xiang-Zhi Zhang; Xiao-Yuan Zheng; Ming-Sheng Chen; Qiu-Yu Zhuang; Bi-Xing Zhao; Cong-Sheng Liu; Xiao-Long Liu; Qin Li; Ying-Chao Wang
Journal:  Chin J Integr Med       Date:  2022-08-10       Impact factor: 2.626

2.  Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer.

Authors:  Rui Nian; Huihui Jiang; Jiangman Zhao; Wanle Hou; Hua Zhang; Jiangtao Ma; Pengbiao Lv; Lisha Jiang; Yongpan Wang; Yue Xu; Shouxin Wu; Jingwei Lou; Wanjun Li
Journal:  Int J Oncol       Date:  2022-07-07       Impact factor: 5.884

Review 3.  Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.

Authors:  Vincent L Chen; Dabo Xu; Max S Wicha; Anna S Lok; Neehar D Parikh
Journal:  Clin Gastroenterol Hepatol       Date:  2020-04-11       Impact factor: 11.382

4.  Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior?

Authors:  Han Wang; Long-Hai Feng; You-Wen Qian; Zhen-Ying Cao; Meng-Chao Wu; Wen-Ming Cong
Journal:  Ann Transl Med       Date:  2019-09

Review 5.  Biomarkers for hepatocellular carcinoma based on body fluids and feces.

Authors:  Ming-Cheng Guan; Wei Ouyang; Ming-Da Wang; Lei Liang; Na Li; Ting-Ting Fu; Feng Shen; Wan-Yee Lau; Qiu-Ran Xu; Dong-Sheng Huang; Hong Zhu; Tian Yang
Journal:  World J Gastrointest Oncol       Date:  2021-05-15

Review 6.  Targeted therapy for hepatocellular carcinoma.

Authors:  Ao Huang; Xin-Rong Yang; Wen-Yuan Chung; Ashley R Dennison; Jian Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-08-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.